Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoxin Ren

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Science Immunology|July 10, 2021
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic targetYao Wei, Xiaoxin Ren, Phillip M Galbo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2019
PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/LymphomaElaine Y Chung, Yun Mai, Urvi A Shah, et al.
Blood|August 31, 2019
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockadeDaniel A Rauch, Kevin C Conlon, Murali Janakiram, et al.
Developmental Cell|November 14, 2023
A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progressionYu Liu, Peter John, Kenta Nishitani, et al.
Stem Cell Investigation|October 11, 2021
Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world settingAstha Thakkar, Zhu Cui, Stephen Zachary Peeke, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Science Immunology|July 10, 2021
KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic targetYao Wei, Xiaoxin Ren, Phillip M Galbo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2019
PAK Kinase Inhibition Has Therapeutic Activity in Novel Preclinical Models of Adult T-Cell Leukemia/LymphomaElaine Y Chung, Yun Mai, Urvi A Shah, et al.
Blood|August 31, 2019
Rapid progression of adult T-cell leukemia/lymphoma as tumor-infiltrating Tregs after PD-1 blockadeDaniel A Rauch, Kevin C Conlon, Murali Janakiram, et al.
Developmental Cell|November 14, 2023
A SOX9-B7x axis safeguards dedifferentiated tumor cells from immune surveillance to drive breast cancer progressionYu Liu, Peter John, Kenta Nishitani, et al.
Stem Cell Investigation|October 11, 2021
Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world settingAstha Thakkar, Zhu Cui, Stephen Zachary Peeke, et al.
Pageof 2